США - англійська - NLM (National Library of Medicine)

dr. reddy's laboratories inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 250 mg - to reduce the development of drug‑resistant bacteria and maintain the effectiveness of augmentin (amoxicillin/clavulanate potassium) and other antibacterial drugs, augmentin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. augmentin® is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: caused by beta‑lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis . caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis . caused by beta‑lactamase–producing isolates of h. influenzae and m. catarr

США - англійська - NLM (National Library of Medicine)

neopharma inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - to reduce the development of drug‑resistant bacteria and maintain the effectiveness of augmentin (amoxicillin/clavulanate potassium) and other antibacterial drugs, augmentin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. augmentin®  is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*:  caused by beta‑lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis .  caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis .  caused by beta‑lactamase–producing isolates of h. influenzae and m. cat

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 286.9 mg (equivalent: amoxicillin trihydrate, qty 250 mg); potassium clavulanate, quantity: 149.5 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; dimeticone 200; titanium dioxide; propylene glycol; hypromellose; ethylcellulose - augmentin is indicated in the treatment of the following infections when caused by augmentin sensitive, beta-lactamase producing organisms: skin and skin structure infections, including cases caused by beta-lactamase producing s. aureus, e. coli and klebsiella spp. (only some strains may be sensitive). urinary tract infections, including cases caused by beta-lactamase producing e. coli, p. mirabilis & klebsiella spp. upper respiratory tract infections, such as sinusitis, including cases caused by beta-lactamase producing h.influenzae and m.catarrhalis, and otitis media, especially cases caused by beta-lactamase producing h. influenzae, m. catarrhalis and s. aureus. lower respiratory tract infections, especially cases caused by beta-lactamase producing h.influenzae and m.catarrhalis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin. however, when there is reason to believe an infection may involve any

Індія - англійська - Central Drugs Standard Control Organization

augment rem. - povidone iodine,metronidazole - oint - 15g

Сінгапур - англійська - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - amoxycillin trihydrate eqv amoxycillin; potassium clavulanate eqv clavulanic acid - tablet, film coated - 500 mg - amoxycillin trihydrate eqv amoxycillin 500 mg; potassium clavulanate eqv clavulanic acid 125 mg

Сінгапур - англійська - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - amoxycillin trihydrate 1004.43mg eqv amoxycillin; potassium clavulanate 148.91mg eqv clavulanic acid - tablet, film coated - 875 mg - amoxycillin trihydrate 1004.43mg eqv amoxycillin 875 mg; potassium clavulanate 148.91mg eqv clavulanic acid 125 mg

Ізраїль - англійська - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as sodium; clavulanic acid as potassium clavulanate - powder for solution for inj/inf - amoxicillin as sodium 500 mg; clavulanic acid as potassium clavulanate 100 mg - amoxicillin and enzyme inhibitor - augmentin is indicated for the treatment of the following infections in adults and children: severe infections of the ear, nose and throat (such as mastoiditis, peritonsillar infections, epiglottitis, and sinusitis when accompanied by severe systemic signs and symptoms), acute exacerbations of chronic bronchitis (adequately diagnosed), community acquired pneumonia. cystitis, pyelonephritis, skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis, bone and joint infections, in particular osteomyelitis, intra-abdominal infections, female genital infections. prophylaxis against infections associated with major surgical procedures in adults, such as those involving the: gastrointestinal tract, pelvic cavity, head and neck, biliary tract surgery..

Ізраїль - англійська - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as sodium; clavulanic acid as potassium clavulanate - powder for solution for inj/inf - amoxicillin as sodium 1000 mg; clavulanic acid as potassium clavulanate 200 mg - amoxicillin and enzyme inhibitor - augmentin is indicated for the treatment of the following infections in adults and children: severe infections of the ear, nose and throat (such as mastoiditis, peritonsillar infections, epiglottitis, and sinusitis when accompanied by severe systemic signs and symptoms), acute exacerbations of chronic bronchitis (adequately diagnosed), community acquired pneumonia. cystitis, pyelonephritis, skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis, bone and joint infections, in particular osteomyelitis, intra-abdominal infections, female genital infections. prophylaxis against infections associated with major surgical procedures in adults, such as those involving the: gastrointestinal tract, pelvic cavity, head and neck, biliary tract surgery.

Європейський Союз - англійська - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastic agents - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

lexon (uk) ltd - amoxicillin trihydrate; clavulanic acid (in the form of potassium clavulanate) - film-coated tablet - 875/125 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor